Companies Dianthus Therapeutics, Inc. /DE/
Dianthus Therapeutics, Inc. /DE/ (DNTH): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Dianthus Therapeutics, Inc. /DE/’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers95th pct.Of 19 peer CEOs
CEO pay, last three years
- $496,022FY2023
- $8,843,300FY2024
- $10,614,702FY2025
CEO total pay was $10,614,702 in fiscal 2025, up from $8,843,300 in fiscal 2024.
FY2025: salary $630,000 · bonus $0 · stock awards $0 · option awards $9,450,952
Executives and directors
Marino Garcia · CEORyan Savitz · CFOSimrat Randhawa · EVPAlison F. Lawton · Independent DirectorAnne McGeorge · Independent DirectorJonathan Violin, Ph.D · Independent DirectorLeon O. Moulder Jr · Former director (through FY2025)Paula Soteropoulos · Independent DirectorSimon Read, Ph.D · Independent DirectorSteven Romano, M.D · Independent DirectorSujay Kango · Independent DirectorTomas Kiselak · Former director (through FY2025)
Frequently asked questions
Who was the highest-paid executive at Dianthus Therapeutics, Inc. /DE/ in fiscal 2025?
As disclosed, Marino Garcia (Director, President and Chief Executive Officer) was the highest-paid executive at Dianthus Therapeutics, Inc. /DE/ in fiscal 2025, with total compensation of $10,614,702.
How does Dianthus Therapeutics, Inc. /DE/'s chief executive pay compare to its disclosed peer group?
As disclosed, Marino Garcia's total compensation ranked at the 95th percentile of Dianthus Therapeutics, Inc. /DE/'s disclosed peer group.
How did shareholders vote on Dianthus Therapeutics, Inc. /DE/'s executive compensation?
As disclosed, 95.99% of shareholders supported Dianthus Therapeutics, Inc. /DE/'s executive compensation in the latest say-on-pay vote.
How much does Dianthus Therapeutics, Inc. /DE/ spend in total on board compensation for fiscal 2025?
As disclosed, Dianthus Therapeutics, Inc. /DE/ reported total board compensation of $402,156 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Marino Garcia | $630,000 | $0 | $0 | $9,450,952 | $519,750 | $0 | $14,000 | $10,614,702 |
| Director, President and Chief Executive Officer | ||||||||
| Simrat Randhawa | 530,555 | 0 | 0 | 4,288,857 | 388,125 | 0 | 14,000 | 5,221,537 |
| Executive Vice President, Head of Research and Development | ||||||||
| Ryan Savitz | 482,560 | 0 | 0 | 4,288,857 | 289,536 | 0 | 14,000 | 5,074,953 |
| Executive Vice President, Chief Financial Officer, Chief Business Officer and Treasurer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Marino Garcia | $10,614,702 | $8,843,300 | $496,022 | ↑ +1,771,402 |
| Simrat Randhawa | 5,221,537 | 4,035,266 | 338,158 | ↑ +1,186,271 |
| Ryan Savitz | 5,074,953 | 4,002,145 | 329,651 | ↑ +1,072,808 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Company's compensation program is designed to attract and retain qualified executives, align executive interests with stockholders, and reward performance. Base salary and total direct cash compensation are targeted at approximately the 50th percentile of the market.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards, LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Simrat Randhawa | Option | 7,997 | 8.44 | — |
| Ryan Savitz | Option | 15,599 | 8.44 | — |
| Ryan Savitz | Option | 56,250 | 37.87 | — |
| Simrat Randhawa | Option | 56,250 | 37.87 | — |
| Ryan Savitz | Option | 60,423 | 21.77 | — |
| Simrat Randhawa | Option | 60,423 | 21.77 | — |
| Ryan Savitz | Option | 62,500 | 17.88 | — |
| Simrat Randhawa | Option | 62,500 | 17.88 | — |
| Marino Garcia | Option | 112,500 | 39.95 | — |
| Ryan Savitz | Option | 115,625 | 22.07 | — |
| Simrat Randhawa | Option | 115,625 | 22.07 | — |
| Marino Garcia | Option | 143,233 | 17.88 | — |
| Marino Garcia | Option | 146,822 | 21.77 | — |
| Marino Garcia | Option | 262,087 | 22.07 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Sujay KangoIndependent · Newly elected | $37,950 | — | $380,910 | — | — | $418,860 |
| Simon Read, Ph.DIndependent · Nominating and Corporate Governance · Science and Technology · Newly elected | 30,357 | — | 351,952 | — | — | 382,309 |
| Alison F. LawtonIndependent · Audit · Nominating and Corporate Governance (Chair) | 87,311 | — | 172,476 | — | — | 259,787 |
| Anne McGeorgeIndependent · Audit (Chair) · Nominating and Corporate Governance · Compensation | 59,906 | — | 172,476 | — | — | 232,382 |
| Paula SoteropoulosIndependent · Audit · Compensation | 59,311 | — | 172,476 | — | — | 231,787 |
| Steven Romano, M.DIndependent · Science and Technology (Chair) | 53,171 | — | 172,476 | — | — | 225,647 |
| Jonathan Violin, Ph.DIndependent · Science and Technology | 45,000 | — | 172,476 | — | — | 217,476 |
| Leon O. Moulder JrIndependent · Departed during FY | 19,847 | — | 0 | — | — | 19,847 |
| Tomas KiselakIndependent · Departed during FY | 9,303 | — | 0 | — | — | 9,303 |
| Marino GarciaEmployee director | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 12,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $402,156 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $402,156 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Dianthus Therapeutics, Inc. /DE/ as a peer
Companies that benchmark against DNTH
4 companies name DNTH as a compensation peer
The list of companies that name DNTH as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
KYTX Kyverna Therapeutics, Inc.ANAB Anaptysbio, IncATXS Astria Therapeutics, Inc.INZY Inozyme Pharma, Inc.LBPH Longboard Pharmaceuticals, Inc.PEPG Pepgen Inc.ANNX Annexon, Inc.GPCR Structure Therapeutics Inc.AURA Aura Biosciences, Inc.DYN Dyne Therapeutics, Inc.STOK Stoke Therapeutics, Inc.SYRE Spyre Therapeutics, Inc.APGE Apogee Therapeutics, Inc.FDMT 4D Molecular Therapeutics, Inc.IRON Disc Medicine, Inc.VERA Vera Therapeutics, Inc.KYMR Kymera Therapeutics, Inc.CABA Cabaletta Bio, Inc.EWTX Edgewise Therapeutics, Inc.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Stoke Therapeutics, Inc. | 2025 | Ian Smith | $170,625 | $11,590,000 | $14,035,067 | $0 | $27,031,655 |
| 2 | Dianthus Therapeutics, Inc. /DE/ | 2025 | Marino Garcia | 630,000 | 0 | 9,450,952 | 519,750 | 10,614,702 |
| 3 | Disc Medicine, Inc. | 2025 | John Quisel | 695,000 | 4,285,817 | 4,441,046 | 554,263 | 9,986,626 |
| 4 | Kymera Therapeutics, Inc. | 2025 | Nello Mainolfi | 693,000 | 0 | 7,318,859 | 519,750 | 8,545,609 |
| 5 | Structure Therapeutics Inc. | 2025 | Raymond Stevens | 672,094 | 2,387,996 | 4,846,926 | 508,871 | 8,429,887 |
| 6 | Edgewise Therapeutics, Inc. | 2025 | Kevin Koch | 670,000 | 1,171,625 | 5,041,621 | 462,300 | 7,359,546 |
| 7 | Vera Therapeutics, Inc. | 2025 | Marshall Fordyce | 660,000 | 2,356,285 | 3,415,725 | 554,400 | 6,986,410 |
| 8 | Spyre Therapeutics, Inc. | 2025 | Cameron Turtle | 665,000 | 0 | 5,552,886 | 475,475 | 6,707,361 |
| 9 | Astria Therapeutics, Inc. | 2024 | Jill Milne | 637,868 | 0 | 5,637,078 | 318,934 | 6,604,416 |
| 10 | Anaptysbio, Inc | 2025 | Daniel Faga | 706,011 | 1,592,001 | 3,345,653 | 465,968 | 6,133,943 |
| 11 | Aura Biosciences, Inc. | 2025 | Elisabet de los Pinos | 645,483 | 1,492,378 | 1,513,293 | 284,013 | 3,956,167 |
| 12 | Annexon, Inc. | 2025 | Douglas Love | 670,833 | 0 | 2,522,260 | 371,250 | 3,579,202 |
| 13 | Pepgen Inc. | 2025 | James McArthur | 619,000 | 170,620 | 2,088,547 | 0 | 3,316,783 |
| 14 | Inozyme Pharma, Inc. | 2024 | Douglas Treco | 541,667 | 0 | 1,933,375 | 0 | 2,485,392 |
| 15 | Cabaletta Bio, Inc. | 2025 | Steven Nichtberger | 659,550 | 0 | 1,266,978 | 446,982 | 2,401,555 |
| 16 | Dyne Therapeutics, Inc. | 2025 | John Cox | 721,000 | 0 | 937,893 | 410,970 | 2,076,868 |
| 17 | Longboard Pharmaceuticals, Inc. | 2023 | Kevin Lind | 610,000 | 0 | 986,934 | 442,860 | 2,053,804 |
| 18 | 4D Molecular Therapeutics, Inc. | 2025 | David Kirn | 667,252 | 0 | 822,750 | 560,597 | 2,051,343 |
| 19 | Kyverna Therapeutics, Inc. | 2025 | Warner Biddle | 625,000 | 0 | 543,804 | 468,750 | 1,814,980 |
| 20 | Apogee Therapeutics, Inc. | 2025 | Michael Henderson | 700,000 | 0 | 0 | 591,500 | 1,291,500 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ | not disclosed | not disclosed | not disclosed | Alpine Rewards, LLC |
| 4D Molecular Therapeutics, Inc. | 140% | Options 100 | not disclosed | Radford (part of the Rewards Solutions practice at Aon plc) |
| Anaptysbio, Inc | 110% | not disclosed | No | Alpine Rewards |
| Annexon, Inc. | 100% of target% | not disclosed | not disclosed | Alpine Rewards |
| Apogee Therapeutics, Inc. | not disclosed | Option 100 | not disclosed | Alpine Rewards |
| Astria Therapeutics, Inc. | not disclosed | Option 100 | not disclosed | Aon |
| Aura Biosciences, Inc. | not disclosed | not disclosed | not disclosed | Pay Governance |
| Cabaletta Bio, Inc. | 114.49% | Option 100 | not disclosed | Aon |
| Disc Medicine, Inc. | 145% | RSU 50 · Options 50 | not disclosed | Pearl Meyer |
| Dyne Therapeutics, Inc. | 95% | not disclosed | not disclosed | Alpine Rewards, LLC |
| Edgewise Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Alpine |
| Inozyme Pharma, Inc. | not disclosed | not disclosed | not disclosed | Alpine Rewards |
| Kymera Therapeutics, Inc. | 125% | not disclosed | No | Alpine Rewards |
| Kyverna Therapeutics, Inc. | not disclosed | Option 100 | not disclosed | Aon plc |
| Longboard Pharmaceuticals, Inc. | not disclosed | Option 100 | not disclosed | Frederic W. Cook & Co. |
| Pepgen Inc. | not disclosed | not disclosed | not disclosed | Pay Governance, LLC |
| Spyre Therapeutics, Inc. | 130% | Option 100 | not disclosed | Alpine Rewards |
| Stoke Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Structure Therapeutics Inc. | 125% | Options 67 · RSU 33 | No | Aon |
| Vera Therapeutics, Inc. | not disclosed | RSU 50 · Options 50 | not disclosed | Alpine Rewards |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-21 | 41,004,507 | 1,713,043 | 500,964 | 95.99% | Passed |
| 2025 | 2025-05-22 | 22,132,031 | 3,684,797 | 9,129 | 85.73% | Passed |
| 2024 | 2024-05-23 | 22,996,759 | 26,822 | 8,360 | 99.88% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-05-21 | 95.99%a |
| 2025 | 2025-05-22 | 85.73%b |
| 2024 | 2024-05-23 | 99.88%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes (if any) will not be counted as votes cast on the matter and will have no effect on the outcome of the proposal.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (38 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Marino Garcia. DEF 14A, filed 2026-04-09. Section “Executive Compensation” · page 17. As printed: 10,614,702. View filing ↗
- Section 01, Simrat Randhawa. DEF 14A, filed 2026-04-09. Section “Executive Compensation”. As printed: 5,221,537. View filing ↗
- Section 01, Ryan Savitz. DEF 14A, filed 2026-04-09. Section “Executive Compensation”. As printed: 5,074,953. View filing ↗
- Section 08, Sujay Kango. DEF 14A, filed 2026-04-09. Section “Director Compensation”. As printed: 418,860. View filing ↗
- Section 08, Simon Read, Ph.D. DEF 14A, filed 2026-04-09. Section “Director Compensation”. As printed: 382,309. View filing ↗
- Section 08, Alison F. Lawton. DEF 14A, filed 2026-04-09. Section “Director Compensation”. As printed: 259,787. View filing ↗
- Section 08, Anne McGeorge. DEF 14A, filed 2026-04-09. Section “Director Compensation”. As printed: 232,382. View filing ↗
- Section 08, Paula Soteropoulos. DEF 14A, filed 2026-04-09. Section “Director Compensation”. As printed: 231,787. View filing ↗
- Section 08, Steven Romano, M.D. DEF 14A, filed 2026-04-09. Section “Director Compensation”. As printed: 225,647. View filing ↗
- Section 08, Jonathan Violin, Ph.D. DEF 14A, filed 2026-04-09. Section “Director Compensation”. As printed: 217,476. View filing ↗
- Section 08, Leon O. Moulder Jr. DEF 14A, filed 2026-04-09. Section “Director Compensation”. As printed: 19,847. View filing ↗
- Section 08, Tomas Kiselak. DEF 14A, filed 2026-04-09. Section “Director Compensation”. As printed: 9,303. View filing ↗
- Section 08, Marino Garcia. DEF 14A, filed 2026-04-09. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-05-22. Item 5.07 · say-on-pay result. As reported: 95.99% (votes for as printed: 41,004,507). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-05-22. Item 5.07 · say-on-pay result. As reported: 85.73% (votes for as printed: 22,132,031). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-05-28. Item 5.07 · say-on-pay result. As reported: 99.88% (votes for as printed: 22,996,759). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 402,156 + equity 0 + all other 0 = 402,156, summed across the director compensation table rows.
- Stoke Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Stoke Therapeutics, Inc.'s own proxy. As printed: 27,031,655. View filing ↗
- Dianthus Therapeutics, Inc. /DE/ (subject), Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in Dianthus Therapeutics, Inc. /DE/'s own proxy. As printed: 10,614,702. View filing ↗
- Disc Medicine, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Disc Medicine, Inc.'s own proxy. As printed: 9,986,626. View filing ↗
- Kymera Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Kymera Therapeutics, Inc.'s own proxy. As printed: 8,545,609. View filing ↗
- Structure Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Structure Therapeutics Inc.'s own proxy. As printed: 8,429,887. View filing ↗
- Edgewise Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Edgewise Therapeutics, Inc.'s own proxy. As printed: 7,359,546. View filing ↗
- Vera Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in Vera Therapeutics, Inc.'s own proxy. As printed: 6,986,410. View filing ↗
- Spyre Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-10. CEO total compensation as printed in Spyre Therapeutics, Inc.'s own proxy. As printed: 6,707,361. View filing ↗
- Astria Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-28. CEO total compensation as printed in Astria Therapeutics, Inc.'s own proxy. As printed: 6,604,416. View filing ↗
- Anaptysbio, Inc, Section 10b CEO total. DEF 14A, filed 2026-06-29. CEO total compensation as printed in Anaptysbio, Inc's own proxy. As printed: 6,133,943. View filing ↗
- Aura Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in Aura Biosciences, Inc.'s own proxy. As printed: 3,956,167. View filing ↗
- Annexon, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Annexon, Inc.'s own proxy. As printed: 3,579,202. View filing ↗
- Pepgen Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Pepgen Inc.'s own proxy. As printed: 3,316,783. View filing ↗
- Inozyme Pharma, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Inozyme Pharma, Inc.'s own proxy. As printed: 2,485,392. View filing ↗
- Cabaletta Bio, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Cabaletta Bio, Inc.'s own proxy. As printed: 2,401,555. View filing ↗
- Dyne Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Dyne Therapeutics, Inc.'s own proxy. As printed: 2,076,868. View filing ↗
- Longboard Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2024-04-12. CEO total compensation as printed in Longboard Pharmaceuticals, Inc.'s own proxy. As printed: 2,053,804. View filing ↗
- 4D Molecular Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in 4D Molecular Therapeutics, Inc.'s own proxy. As printed: 2,051,343. View filing ↗
- Kyverna Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-13. CEO total compensation as printed in Kyverna Therapeutics, Inc.'s own proxy. As printed: 1,814,980. View filing ↗
- Apogee Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Apogee Therapeutics, Inc.'s own proxy. As printed: 1,291,500. View filing ↗